Leaders at the U.S. Food and Drug Administration have pressed internally for reviewers to speed up their evaluation of Eli ...

Leaders at the U.S. Food and Drug Administration have pressed internally for reviewers to speed up their evaluation of Eli ...

A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial ...

Big American drugmakers are hunting for novel weight loss drugs in the labs of China’s biotech industry, while U.S.

Regeneron is finding ways to deal with the increased competition to one of its key growth drivers. The company is also ...

The Commissioner’s National Priority Voucher program was launched in June to shorten review times for companies that align ...

An Institute for Value-Based Medicine ® event held in New Haven, Connecticut, on October 30, 2025, brought together a diverse ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Get the latest stock market and healthcare sector updates, top gainers and losers, and key regulatory news impacting investments.

Eli Lilly said its next generation weight-loss drug retatrutide resulted in significant weight loss and reduced knee pain in ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

A weight loss drug dubbed the "triple G" drug for its effectiveness in mimicking three hunger-regulating hormones showed promising results in new data released Thursday by its maker, Eli Lilly.